mTORC1-s6k activation by endotoxin contributes to cytokine up-regulation and early lethality in animals

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Lee, Po Shun ^a,b   Wilhelmson, Anna S K ^c,d   Hubner, Anton P ^d   Reynolds, Samuel B ^a   Gallacchi, Dana A ^a   Chiou, Terry T ^a   Kwiatkowski, David J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CYTOKINE; ENDOTOXIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MTORC1 COMPLEX, MOUSE; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTOXEMIA; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; INFLAMMATION; KIDNEY; LIVER; LUNG; MACROPHAGE; MALE; MORTALITY; MOUSE; NONHUMAN; SINGLE DRUG DOSE; SURVIVAL RATE; UPREGULATION; ANIMAL; METABOLISM; MUTATION; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALIA; MAMMALIA; MUS;

ANIMALS; CYTOKINES; ENDOTOXEMIA; ENDOTOXINS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; LIPOPOLYSACCHARIDES; MALE; MAP KINASE KINASE 1; MICE; MUTATION; PHOSPHORYLATION; PROTEINS; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 78650990015     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014399     Document Type: Article

References (27)

1. Sabatini DM (2006) MTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729-734.
2. Thomson AW, Turnquist HR, Raimondi G (2009) Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9: 324-337.
3. Davies SP, Reddy H, Caivano M, Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
4. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124: 471-484.
5. Lorne E, Zhao X, Zmijewski JW, Liu G, Park YJ, et al. (2009) Participation of mammalian target of rapamycin complex 1 in Toll-like receptor 2- and 4- induced neutrophil activation and acute lung injury. Am J Respir Cell Mol Biol 41: 237-245.
6. Ohtani M, Nagai S, Kondo S, Mizuno S, Nakamura K, et al. (2008) Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood 112: 635-643.
7. Schmitz F, Heit A, Dreher S, Eisenacher K, Mages J, et al. (2008) Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol 38: 2981-2992.
8. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, et al. (2008) The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29: 565-577.
9. Delgoffe GM, Powell JD (2009) MTOR: taking cues from the immune microenvironment. Immunology 127: 459-465.
10. Weichhart T, Saemann MD (2009) The multiple facets of mTOR in immunity. Trends Immunol 30: 218-226.
11. Kimball SR, Orellana RA, O'Connor PM, Suryawan A, Bush JA, et al. (2003) Endotoxin induces differential regulation of mTOR-dependent signaling in skeletal muscle and liver of neonatal pigs. Am J Physiol Endocrinol Metab 285: E637-644.
12. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, et al. (1998) TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160: 943-952.
13. Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, et al. (2008) Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 28: 5422-5432.
14. Meikle L, Talos DM, Onda H, Pollizzi K, Rotenberg A, et al. (2007) A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci 27: 5546-5558.
15. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, et al. (2003) Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 112: 1223-1233.
16. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, et al. (2007) IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130: 440-455.
17. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC, Jr., et al. (1996) Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 15: 5256-5267.
18. Ballou LM, Lin RZ (2008) Rapamycin and mTOR kinase inhibitors. J Chem Biol 1: 27-36.
19. Dunne A, O'Neill LA (2003) The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003: re3.
20. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121: 179-193.
21. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3Kdependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.
22. El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ (2003) Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 63: 5173-5177.
23. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128-135.
24. Thickett DR, Armstrong L, Christie SJ, Millar AB (2001) Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome. Am J Respir Crit Care Med 164: 1601-1605.
25. Yano K, Liaw PC, Mullington JM, Shih SC, Okada H, et al. (2006) Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 203: 1447-1458.
26. Kaur S, Lal L, Sassano A, Majchrzak-Kita B, Srikanth M, et al. (2007) Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem 282: 1757-1768.
27. Kaur S, Sassano A, Dolniak B, Joshi S, Majchrzak-Kita B, et al. (2008) Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci U S A 105: 4808-4813.